AAJ HAS UPDATED ITS PRIVACY POLICY AND USES COOKIES ON THIS SITE. To acknowledge and accept AAJ’s privacy policy with the use of cookies, please select OK, I Accept.

Review AAJ's Privacy Policy
Litigation Groups


Provide litigation support and education to AAJ members who represent female claimants in litigation involving the prescription drug Lipitor.

Litigation Group Join


Lipitor—also known as atorvastatin calcium—is an HMG-CoA reductase inhibitor (statin) and is designed to lower LDL cholesterol and triglycerides. Lipitor was brought to market in the United States by Warner-Lambert Company in late 1996. At the time of launch and before, Warner-Lambert knew or should have known that Lipitor could cause patients to develop Type II diabetes but failed to warn prescribers and patients of this risk.

Following launch, Lipitor was marketed by Warner-Lambert and Pfizer, Inc. under a comarketing agreement, and in June 2000, Pfizer acquired Warner-Lambert and all rights to Lipitor. Pfizer continued to aggressively market Lipitor, and Lipitor became the world’s largest selling pharmaceutical drug in history, with more than $125 billion in sales before it went generic in late 2011. One of the primary rationales for prescribing Lipitor was based on the marketing claim that, by more dramatically lowering the “bad” cholesterol than other statins, Lipitor was more effective than other statins at preventing heart disease. However, there is no credible evidence that Lipitor will prevent heart disease in
women, yet women are at a substantially increased risk over men of developing Type II diabetes from Lipitor.

In February 2012, and in response to a request from FDA, the following language was finally added by Pfizer to the Warnings and Precaution Sections of the Lipitor label: “Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including LIPITOR.” However, even this label change was inadequate because it fails to advise prescribers and patients of the causal connection between Lipitor and Type II diabetes.

This Litigation Group was formed in 2013. This Litigation Group will provide litigation support and education to AAJ members who represent female claimants in litigation involving the prescription drug Lipitor. The Lipitor Litigation Group member benefits include a group document library, list server, and education programs.


AAJ Annual and Winter Conventions, or as needed by group members.


Open to Regular, Sustaining, Life, Leaders Forum, President's Club and Paralegal Affiliate members.


$500/attorney, $200/additional attorney from firm

Join the Conversation

Litigation Group members, visit AAJ's Community Center to connect with your colleagues on the list server, search discussion archives, download documents, update your list server settings, and more. Lit Group Member Login